| | Total cohort | Main study group, ≥ 3 days of survival |
|---|
Total | Methadone in CSCI | No methadone in CSCI |
|---|
| | n = 93 | n = 47 | n = 13 | n = 34 |
|---|
| | Day 0 | Day 0 | Day 3 | Day 0 | Day 3 | Day 0 | Day 3 |
|---|
Alertnessa |
Mean (SD) | −0.5 (1.2) | −0.2 (1) | −1.2 (1,7)*** | 0.4 (0.9) | −0.9 (1.7)* | − 0.4 (1) | −1.3 (1.7)* |
Median (IQR) | 0 (1) | 0 (2) | −1 (2) | 0 (1) | 0 (2) | −0.5 (1) | −1 (2) |
Deliriumb |
Prevalence n (%) | 27 (29) | 14 (30) | 15 (32) | 4 (31) | 5 (39) | 10 (29) | 10 (29) |
Prev. < 75 years | 12 (32) | 7 (33) | 9 (43) | 4 (31) | 5 (39) | 8 (32) | 7 (28) |
Prev. ≥ 75 years | 15 (27) | 7 (27) | 6 (23) | 3 (30) | 2 (20) | 12 (27) | 4 (9) |
Anxiety c |
median (IQR) | 3 (1) | 3 (1) | 2 (2) | 3 (1) | 2 (1.8) | 3 (1.5) | 2 (2) |
- aOrdinal scale from + 4 (combative) to −5 (unarousable)
- bPrevalence of confusion/delirium (Yes/No)
- cOrdinal scale from 0 (not at all) to 4 (always)
- Significance of differences from day 0 to day 3:*p < 0.05; ***p ≤ 0.001
- In this table, the status of all 93 patients regarding alertness, prevalence of delirium and anxiety on the day of initiation, day 0, of continuous subcutaneous infusion (CSCI) is reported under total cohort. The main study group is the 47 patients who survived at least 3 days. The changes from day 0 to day 3 in adverse effects is shown for the total group and also for the 13 patients who received methadone in CSCI and the 34 patients who did not.
- (n number of patients, SD standard deviation, IQR inter quartile range)
